Kornimate/medical-research-clean huggingface dataset:
oxidative stress, carbohydrate metabolism disorders and g6pd deficiency

Conditions: G6PD Deficiency; Carbohydrate Metabolism Disorder; Oxidative Stress

Summary: the purpose of this study is to investigate the effects of alpha-lipoic acid supplementation on redox status, physiological and biochemical parameters in diabetic individuals with g6pd deficiency, after acute exercise.

in a randomized double-blind, crossover design, a total of forty people will participate in the research voluntarily: (a) ten people with g6pd (mediterranean type) enzyme deficiency), (b) ten people with g6pd (mediterranean type) enzyme deficiency and a disorder of carbohydrate metabolism (diabetes, prediabetes), (c) ten people with a disorder of carbohydrate metabolism (diabetes mellitus and prediabetes) and, (d) ten people without any health problem (control group). they will be supplemented with either 600 mg of alpha-lipoic acid (experimental condition) or placebo (control condition) every day for 4 weeks, separated by a 4-week washout period. all participants will be randomly assigned to both conditions. before intervention, all participants will be informed about the study protocol, fill a medical history questionnaire and sign an informed consent form. moreover, measurements of anthropometric characteristics and physiological parameters, as well as a vo2peak test will be performed. participants will perform a trial of exercise (70% vo2peak for 45min and 90% till exhaustion) before and after each condition (i.e. a total of 4 trials). blood samples will be collected before, immediately after and 1 hour after each exercise trial. moreover, measurements of anthropometric characteristics, physiological and psychological parameters will be performed before and after each condition.

Eligibility criteria:
inclusion criteria: * individuals with normal g6pd activity * individuals with g6pd deficiency * individuals with cho metabolism disorders (diabetes, prediabetes) * individuals with g6pd deficiency and cho metabolism disorders (diabetes, prediabetes) exclusion criteria: * health problems that contraindicate participation to exercise * should not take any medication that affects the body's antioxidant mechanisms as well as dietary supplements containing antioxidants * women during lactation or gestation
phase2, single group, open clinical trial to evaluate the efficacy and safety of roflumilast in symptomatic bronchiectasis patients

Conditions: Symptomatic Bronchiectasis

Summary: there is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable copd. we hypothesized that roflumilast might be effective in symptomatic bronchiectasis patients


Eligibility criteria:
inclusion criteria: * bronchiectasis on ct * chronic (\>3 months) cough or sputum exclusion criteria: * needs hospitalization * life expectancy of less than six months * pregnancy or breast feeding * history of acute respiratory infection within 4 weeks * history of taking antibiotics within 4 weeks * active hemoptysis * %predicted fev \< 30% * severe liver disease (child pugh class b or c)
possible roles of mdw in infection management in emergency care

Conditions: Infection; Sepsis

Summary: a retrospective study to determine the potential value of mdw among other biomarkers in the diagnosis of infection.

mdw as a novel indicator can be useful in clinical practice in the emergency care. however, until now, no study has been published about mdw's general relationship and coherence with multiple, conventional laboratory tests for infections, such as pct, c-reactive protein (crp), wbc, neutrophil count (nc), neutrophil percentage and immature granulocyte count (igc) together.

Eligibility criteria:
inclusion criteria: * adult (18+ years), receiving care for suspected infection exclusion criteria: * refuses to sign the consent form
a study evaluating apg777 in atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a two-part study that will evaluate the safety and efficacy of apg777 in participants with moderate-to-severe atopic dermatitis (ad). part a (proof-of-concept) and part b (dose-regimen finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of apg777 compared to placebo. the study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. participants randomized in part a are not permitted to participate in part b.


Eligibility criteria:
inclusion criteria: * have a diagnosis of ad that has been present for \>=1 year prior to the screening visit * moderate-to-severe ad at screening and baseline visits * history of inadequate response to treatment with topical medications, or medical determination that topical therapies are inadvisable * applied a stable dose of non-medicated over-the-counter emollient/moisturizer of their choice on their skin for \>=14 days prior to baseline visit and agrees to continue using the same moisturizer throughout the study except the day of the study visits. * have completed itch questionnaires in the electronic diary for \>=4 of 7 days prior to baseline visit exclusion criteria: * participation in a prior study with apg777. * prior treatment with protocol-specified monoclonal antibodies (mabs) * has used any ad-related topical medications within 7 days prior to baseline visit. * has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect ad within 4 weeks prior to baseline visit note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: atopic dermatitis apg777 safety efficacy
brazilian registry of menopausal

Conditions: Menopause

Summary: this national study aims to better understand the health and quality of life of brazilian women aged 35 to 65 who are in the menopausal transition or postmenopausal phase, including cisgender women and transgender men who have not undergone surgical or hormonal reassignment of secondary sexual characteristics. the study's hypothesis is that significant regional and socioeconomic disparities influence individuals' health, knowledge, and perception of menopause.

this is a descriptive, cross-sectional, population-based study conducted with the objective of characterizing the epidemiological aspects of the brazilian population during the menopausal transition and postmenopause, as well as the factors associated with clinical profiles and symptomatology, socioeconomic conditions, social inequalities, access to healthcare services, quality of life, and knowledge about menopause. the study will include cisgender women and transgender men who have not undergone surgical or hormonal gender reassignment of secondary sexual characteristics, aged between 35 and 65 years, who seek outpatient care in public or private healthcare services. a total of 1,592 participants will be enrolled, with 617, 509, and 466 women in the respective age groups of 35-44, 45-54, and 55-65 years, proportionally stratified across the 27 state capitals of brazil. these age groups will be used solely for the purpose of sample stratification.

Eligibility criteria:
inclusion criteria: 1. women aged between 35 and 65 years attending medical consultation at public and private outpatient health services; 2. ability to confirm voluntary participation and sign the informed consent form exclusion criteria: 1. inability to respond to the interview for any reason 2. suspected or confirmed pregnancy 3. lactation 4. uncontrolled diabetes 5. uncontrolled arterial hypertension 6. uncontrolled thyroid disorders 7. grade 3 obesity, defined by a bmi equal to or greater than 40.0 kg/m² 8. diagnosis of psychiatric disorders that may compromise participation in the interview 9. previous hysterectomy 10. previous oophorectomy 11. current use of illicit drugs

Keywords: menopause post menopause menopause transition climateric
lithium and acetate for canavan disease

Conditions: Canavan Disease; Infantile; Deficiency Disease; Aspartoacylase; Leukodystrophy, Spongiform

Summary: the aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with canavan disease.

canavan disease is an autosomal recessive devastating demyelinating disease caused by a deficiency in aspartoacylase (aspa) enzyme. there is no available treatment. aspa deficiency leads to:- the accumulation of high levels of n-acetylaspartate (naa), involved in myelin degeneration and epilepsy;- the deficient synthesis of acetate in oligodendrocytes, that could impair cns myelination.lithium administration induces a decrease in naa in the brain of the tremor rats (animal model for cd) and in one patient (janson, 2005). on the other hand, administration of acetate could improve myelination in canavan patients.for this reason, we propose to combine both treatments: lithium gluconate and glyceryl triacetate (gta). eighteen patients, aged 1 to 15 years, will receive oral gta or lithium during 4 months, then both treatment in association during 6 months. patients will be sequentially evaluated up to the end of the treatment and 2 months thereafter for:-tolerance of the therapy (careful monitoring of clinical and biological parameters).- efficacy of the therapy on clinical, biological and radiological parameters. particularly, we will evaluate using mri-spectroscopy and csf samples the decrease in naa and increase in acetate levels in the brain.

Eligibility criteria:
inclusion criteria: * clinical and biochemical diagnosis of canavan disease exclusion criteria: * renal disease * thyroid disease * cardiac disease * impossibility to perform brain mri

Keywords: leukodystrophy canavan disease, aspartoacylase, lithium, glyceryl triacetate
the effect of single dose paracetamol on the lower airways of asthmatic and healthy children

Conditions: Asthma

Summary: asthma is a common inflammatory airway disease. several researches have demonstrated a possible connection between asthma and exposure to paracetamol. our hypothesis is that even a single dose of paracetamol is sufficient to cause a measurable change in lung functions. this trial aims to identify a possible effect of single dose paracetamol on lower airway function.

asthma is a common inflammatory airway disease and its prevalence is on the rise all around the world, most significantly in children under 5 years. paracetamol is one of the most common drugs used with children at thus age groups and several studies have proved a causative connection between exposure to paracetamol and asthma prevalence as well as other allergic conditions. the mechanism is presumably by reduction of glutathione level, resulting in oxidative burst and formation of reactive oxygen species (ros). in addition, paracetamol maybe directly cytotoxic to pneumocytes if given in overdose. the goal of this research is to identify and quantify the effect of single dose of paracetamol on lung functions of asthmatic and healthy subjects. the study group will include 40 children aged 7-16 years, who are known to have asthma and a control group of 20 healthy children. the children will be randomized to receive a dose of paracetamol or placebo, and lung functions will be measured by both spirometry and fraction of expired nitric oxide (feno) test. each child will receive both paracetamol and placebo, randomly in to consecutive tests, thus children will serve as their own control.

Eligibility criteria:
inclusion criteria: * age: 7-16 years * research group: children who have been diagnosed as asthmatic according to the american thoracic society (ats) criteria * control group: children who are not known to have asthma exclusion criteria: * paracetamol sensitivity * children with any kind of chronic disease (except asthma) * children with non asthma related chronic lung disease * acute asthma attack * children on systemic steroids

Keywords: asthma acetaminophen paracetamol feno spirometry lung function
preparing a food is medicine intervention to promote healthy eating and blood pressure control

Conditions: Hypertension; Obesity; Healthy Nutrition; Blood Pressure

Summary: hypertension and obesity are both major risk factors for cardiovascular disease (cvd), a leading cause of death for black women in the united states. the investigators propose examining the feasibility and acceptability of the 12-week rn-chefrx (real nourishment and cooking healthy food is rx) intervention - grocery delivery, cooking classes, and nutrition education - for black women with hypertension and obesity to improve nutritious eating habits and blood pressure control.

the objective of this study is to conduct the rn-chefrx (real nourishment and cooking healthy food is rx) for 12 weeks among black women who are obese and hypertensive living chicago. we propose to 1) pilot the rn-chefrx intervention and measures that will be used to assess blood pressure, bmi status, and sodium intake with 20 black women diagnosed with hypertension and bmi ≥ 30. we will assess the efficacy of the evaluation tools to be used in a future clinical trial at three-time points (baseline, 12 weeks, and 6 months); and 2) assess the feasibility and acceptability of the rn-chefrx intervention using interviews, surveys, and documentary analysis. findings from this study will inform a larger efficacy trial of rn-chefrx to improve dietary behaviors and blood pressure control among black women with hypertension and obesity.

Eligibility criteria:
inclusion criteria: * self-identified as black or of african descent * female * ≥ 18 years old * baseline blood pressure ≥130/85 or diagnosed with hypertension and bmi ≥ 30 exclusion criteria: * inability to cook in their homes * cognitive deficits impeding the ability to participate or provide informed consent * current treatment for cancer * liver or renal disease * pregnancy * lack of english language proficiency
correction of asymptomatic 2nd degree cystocele in patient with stress incontinence

Conditions: Stress Urinary Incontinence

Summary: the aim of our study is to assess the value of concomitant surgical correction of asymptomatic grade ii anterior vaginal wall prolapse with the placement of midurethral sling for treatment of female patients with stress incontinence

female patients with stress urinary incontinence and asymptomatic grade ii anterior vaginal wall prolapse were divided into group a: treated only with trans-obturator tape (tot) and group b where' tot was associated with anterior colporrhaphy and the outcome is compared.

Eligibility criteria:
inclusion criteria: * female patients * genuine stress incontinence * asymptomatic cystocele exclusion criteria: * mixed incontinence

Keywords: asymptomatic cystocele. stress urinary incontinence
study to assess the efficacy, safety, tolerability, and pharmacokinetics of biib033 in participants with relapsing forms of multiple sclerosis when used concurrently with avonex

Conditions: Multiple Sclerosis

Summary: the primary objective of the study is to evaluate the efficacy of biib033 in participants with active relapsing multiple sclerosis (ms) when used concurrently with avonex. secondary objectives of this study in this study population are to assess the safety, tolerability, and population pharmacokinetics of biib033 when used concurrently with avonex.


Eligibility criteria:
key inclusion criteria: * diagnosis of relapsing remitting ms (rrms) or onset of secondary progressive ms (spms) * rrms and spms subjects must have evidence of ongoing disease activity within 12 months of enrollment. * all male and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment key exclusion criteria: * a ms relapse that has occurred within the 90 days prior to day 1/baseline and/or the subject has not stabilized from a previous relapse prior to screening * previous history of clinically significant disease. * plans to undergo elective major procedures/surgeries at any time during the study. * treatment with any investigational ms drugs within 3 weeks or 5 times the half life (whichever is longer) prior to day 1/baseline * rrms subjects with any history of inadequate response to any approved interferon β preparation * history of human immunodeficiency virus (hiv), hepatitis c virus antibody, or hepatitis b virus * history or evidence of drug or alcohol abuse within 2 years prior to randomization note: other protocol defined inclusion/exclusion criteria may apply.
effects of 5-aminolevulinic acid on iron deficiency anemia

Conditions: Iron Deficiency Anemia

Summary: this study is designed to evaluate efficacy and dose-dependency of 5-aminolevulinic acid in subjects with iron deficiency anemia.


Eligibility criteria:
inclusion criteria: * premenopausal women with hemoglobin ≥ 9.0 g/dl and ≤ 12.0 g/dl * willing not to donate blood during the study * informed consent signed exclusion criteria: * history of porphyria, hemochromatosis, or viral hepatitis * anemia other than iron deficiency * bmi ≤ 18 kg/m2 or ≥ 30 kg/m2 * pregnant or nursing a child * participation in any clinical trial within 90 days of the commencement of the trial * renal or hepatic dysfunction * heart disease * subjects who are taking medicines or functional food that may affect hemoglobin level
open-label, pilot study of tg100801 in patients with choroidal neovascularization due to amd

Conditions: Macular Degeneration; Choroidal Neovascularization

Summary: wet age-related macular degeneration (amd) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. the new blood vessels have fragile walls and can leak fluid into the retina. the build-up of fluid (edema) under the macula can distort vision or cause vision loss. tg100801 is a topical (eye drop) therapy that has been shown to inhibit ocular angiogenesis, vascular leak, and inflammation in laboratory studies. the primary purpose of this pilot study is to evaluate the ability of topical administration of tg100801 to reduce the amount of fluid in the retina in patients with amd following 30 days of treatment. an additional objective is to evaluate the safety of tg100801 in patients with amd.

choroidal neovascularization (cnv) due to amd is the leading cause of irreversible, severe vision loss in people 55 years and older in the developed world. tg100801 is a potent inhibitor of vascular growth endothelial factor (vegf) and other kinases that contribute to cnv and macular edema. animal models have demonstrated the ability of tg100801 to inhibit angiogenesis, vascular leak, and inflammation. tg100801 is being developed as a topical (eye drop) therapy for treatment of cnv due to amd. the primary objective of this multicenter, open-label, randomized, pilot study is to evaluate the effects of 30 days of dosing with two dose levels of tg100801 on central retinal/lesion thickness, as measured by optical coherence tomography (oct). the safety of tg100801 in patients with amd also will be evaluated.

Eligibility criteria:
inclusion criteria: * subfoveal cnv secondary to amd in study eye * cnv lesion size less than or equal to 12 mps disk areas * cnv \> 50% of lesion area * presence of intraretinal fluid causing an increase in central subfield thickness of at least 250 microns, confirmed by oct in study eye * any lesion composition * best corrected visual acuity of 20/40 to 20/320 (73 to 24 etdrs letters) at 4 meters in study eye * best corrected visual acuity of 20/800 or better (at least 4 etdrs letters) at 4 meters in fellow eye * ability to administer and tolerate eye drops * able to give written informed consent exclusion criteria: * history of any treatment for subfoveal cnv in study eye * known or anticipated need for use of topical medication in study eye during 30-day dosing period * current or anticipated need for any available ocular anti-vegf therapy in fellow eye for 30 days prior to and 30 days following baseline * rpe rip or tear in study eye * blood \> 1 disk area, atrophy, or fibrosis (disciform scar) under foveal center of study eye * scarring/fibrosis of at least 25% of total cnv lesion in study eye * hemorrhage or ped \> 50% of total cnv lesion in study eye * glaucoma with visual field loss or iop at least 25 mmhg in study eye or consistently at least 25 mmhg in fellow eye
comparison of 18-f sodium fluoride uptake in culprit plaques between acute coronary syndrome and stable angina

Conditions: Coronary Artery Diseases

Summary: the purpose of this study is to evaluate the correlations between active calcification and vulnerable plaque.


Eligibility criteria:
inclusion criteria: * age more than 20 * acute coronary syndrome or stable angina exclusion criteria: * contraindications to the use of heparin, aspirin, clopidogrel, stainless metal, contrast media * acute st segment elevation myocardial infarction within 12hours, heart failure, cardiac shock * any serious medical comorbidity such that the subject's life expectancy is less than 24 months * ejection fraction less than 30 * serum creatinine level of 1.5mg/dl and over * vasculitis * unwillingness or inability to cooperate or to give informed consent

Keywords: 18-f sodium fluoride acute coronary syndrome stable angina
breast cancer detection: comparison of breast tomosynthesis and conventional mammography

Conditions: Breast Cancer

Summary: the primary hypothesis to be tested is: the detection of breast cancer will be increased with tomosynthesis (3d) imaging

the purpose of this study is to determine if: 1 the detection of breast cancer will be increased with conventional (2d) imaging plus tomosynthesis (3d) imaging, or 2. if the the detection of breast cancer will be increased with tomosynthesis (3d) imaging alone.

Eligibility criteria:
inclusion criteria: * female * any ethnic origin * no contraindication for routine bilateral mammography exclusion criteria: potential subjects with any of the following will not be enrolled in the study: * any contraindications to mammographic screening, including, but not limited to: * significant existing breast trauma * under the age of 30 at the time of consent * breast implants * prior surgeries * unable to understand and execute written informed consent * pregnant * lactating

Keywords: breast cancer imaging